Our group is interested in understanding the molecular mechanisms that contribute to myeloid leukemogenesis, with an emphasis on identifying new opportunities for therapeutic intervention. We are currently focused on characterizing how non-coding RNA, including lncRNA and miRNA, promote malignant phenotypes of cell growth, survival, and self-renewal in normal hematopoietic stem cells and leukemia cells. Another main focus of our research aims to better understand the disease mechanisms of a specific subgroup of acute myeloid leukemia (AML) harboring mutations in the epigenetic modifiers DNMT3A and TET2, and how the regulatory action of non-coding RNA impacts the epigenetic state of AML. Importantly, all of our research has a common underlying goal to exploit these mechanisms as possible therapies to induce leukemia cell death and/or differentiation.